Eli Lilly and Company
LLY · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $684,335 | $699,940 | $741,658 | $692,899 |
| - Cash | $9,792 | $3,376 | $3,093 | $3,268 |
| + Debt | $42,507 | $39,904 | $38,516 | $33,644 |
| Enterprise Value | $717,049 | $736,468 | $777,081 | $723,275 |
| Revenue | $17,601 | $15,558 | $12,729 | $13,533 |
| % Growth | 13.1% | 22.2% | -5.9% | – |
| Gross Profit | $14,593 | $13,110 | $10,504 | $11,129 |
| % Margin | 82.9% | 84.3% | 82.5% | 82.2% |
| EBITDA | $7,882 | $7,504 | $4,163 | $5,748 |
| % Margin | 44.8% | 48.2% | 32.7% | 42.5% |
| Net Income | $5,583 | $5,661 | $2,759 | $4,410 |
| % Margin | 31.7% | 36.4% | 21.7% | 32.6% |
| EPS Diluted | 6.21 | 6.29 | 3.06 | 4.88 |
| % Growth | -1.3% | 105.6% | -37.3% | – |
| Operating Cash Flow | $8,836 | $3,087 | $1,666 | $2,474 |
| Capital Expenditures | -$224 | -$1,804 | -$3,267 | -$1,747 |
| Free Cash Flow | $8,612 | $1,283 | -$1,601 | $727 |